The Pharmacogenetics of Aspirin Resistance - The Pharmacogenetics of Aspirin Resistance

Royal Group of Hospitals Trust0 sites150 target enrollmentMarch 24, 2006

Overview

Phase: Phase 1
Intervention: Not specified
Conditions: Aspirin resistance: Vascular diseases are common problems and aspirin is used as an anti-platelet drug to prevent thrombosis. However, aspirin's anti-platelet effect may not be uniform in all patients. From a biochemical perspective, aspirin resistance refers to patients who do not display an adequate degree of platelet inhibition on formal laboratory tests. Published data suggest that 5 - 45% of patients are 'aspirin resistant'. The mechanisms of aspirin resistance are poorly understood.
Sponsor: Royal Group of Hospitals Trust
Enrollment: 150
Status: Active, not recruiting
Last Updated: 7 years ago

No summary available.

Registry

who.int

Start Date

March 24, 2006

End Date

TBD

Last Updated

7 years ago

Study Type

Interventional clinical trial of medicinal product

Sex

All

Sponsor

Royal Group of Hospitals Trust

•Use of other anti\-platelet drugs (thienopyridines, GPIIb/IIIa antagonists, dipyridamole) because these drugs would also interfere with platelet function assays;
•Use of other non\-steroidal anti\-inflammatory drugs, because of pharmacodynamic interactions;
•History of dyspepsia or peptic ulceration requiring treatment with proton pump inhibitor or H2\-antagonist, in view of the increased risk of gastrointestinal haemorrhagic complications;
•History of systemic inflammatory diseases, in view of the need for these patients to take anti\-inflammatory drugs;
•History of asthma;
•Use of other medications including aspirin (including herbal preparations);
•Family or personal history of bleeding disorders, in order to reduce the potential for haemorrhagic complications;
•Use of oral anticoagulants;
•Platelet count outside the normal range (150,000 \- 450,000 / ml), as these patients require further investigation and aspirin use is contra\-indicated in patients with significant thrombocytopaenia;
•Significant anaemia (Hb \< 10g/dl), as these patients may require further investigation;